(Reuters) – Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients.
Filgotinib is being tested for inflammatory conditions including rheumatoid arthritis and Crohn’s disease. (https://reut.rs/2Tmy9fO)
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)
